Literature DB >> 6455916

In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin.

J L Henderson, R E Polk, B J Kline.   

Abstract

The in vitro inactivation of gentamicin, tobramycin, and netilmicin, when combined with carbenicillin, azlocillin, and mezlocillin, was studied. Plasma samples containing the aminoglycosides at a concentration of 5-8 micrograms/ml in combination with the penicillins in concentrations of 500, 250, and 50 micrograms/ml were incubated at room temperature and 37 degrees C for 0.3, 1, 3, 6, and 9 days. The aminoglycoside concentration was determined by radioimmunoassay or enzyme immunoassay. The extent of inactivation was dependent on penicillin concentration, contact time, and temperature. Penicillin concentrations of 500 micrograms/ml caused the greatest loss of aminoglycoside, while little loss occurred at the 50-micrograms/ml penicillin level. Carbenicillin, in concentrations of 250 and 500 micrograms/ml, inactivated all three aminoglycosides to a greater extent than either azlocillin or mezlocillin. The initial rate of decline in aminoglycoside concentration was greater at 37 degrees C than at room temperature. The new acylureidopenicillins, azlocillin and mezlocillin, inactivate the aminoglycosides studied, in a similar manner to that previously described for carbenicillin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6455916

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  11 in total

1.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly.

Authors:  E Triggs; B Charles
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

4.  Comparative assessment of in vitro inactivation of gentamicin in the presence of carbenicillin by three different gentamicin assay methods.

Authors:  S C Ebert; J H Jorgensen; D J Drutz; W A Clementi
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

5.  Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin.

Authors:  J N Walterspiel; S Feldman; R Van; W R Ravis
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  In vitro interaction of aminoglycosides with beta-lactam penicillins.

Authors:  S M Wallace; L Y Chan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin.

Authors:  H Konishi; M Goto; Y Nakamoto; I Yamamoto; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

Review 8.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

9.  Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.

Authors:  C E Halstenson; M O Wong; C S Herman; K L Heim-Duthoy; M A Teal; M B Affrime; J H Kelloway; W F Keane; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Hydroxylamine technique for in vitro prevention of penicillin inactivation of tobramycin.

Authors:  A J Falkowski; R J Creger
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.